N-(3-aminopropyl)methacrylamide | 86742-39-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-(3-aminopropyl)methacrylamide
• 英文别名: N-(3-aminopropyl)methacrylamide hydrochloride；N-(3-aminopropyl)-2-methylprop-2-enamide
• CAS: 86742-39-4
• 化学式: C₇H₁₄N₂O
• mdl: MFCD07772430
• 分子量: 142.201
• InChiKey: GUAQVFRUPZBRJQ-UHFFFAOYSA-N

物化性质

• 沸点：
  311.4±34.0 °C(Predicted)
• 密度：
  0.956±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.571
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(3-aminopropyl)methacrylamide 在 水 、 N,N'-二环己基碳二亚胺 、 potassium hydroxide 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 5.17h， 生成 4-[3-(2-Methylprop-2-enoylamino)propylcarbamoyl]benzoic acid
  参考文献：
  名称：

  Structural optimization of HPMA copolymer-based dexamethasone prodrug for improved treatment of inflammatory arthritis

  摘要：

  Despite their notorious adverse effects, glucocorticoids (GC, potent anti-inflammatory drugs) are used extensively in clinical management of rheumatoid arthritis (RA) and other chronic inflammatory diseases. To achieve a sustained therapeutic efficacy and reduced toxicities, macromolecular GC prodrugs have been developed with promising outcomes for the treatment of RA. Fine-tuning the activation kinetics of these prodrugs may further improve their therapeutic efficacy and minimize the off-target adverse effects. To assess the feasibility of this strategy, five different dexamethasone (Dex, a potent GC)-containing monomers with distinctively different linker chemistries were designed, synthesized, and copolymerized with N-(2-hydroxypropyl) methacrylamide (HPMA) to obtain 5 macromolecular Dex prodrugs. Their Dex releasing rates were analyzed in vitro and shown to display a wide spectrum of activation kinetics. Their therapeutic efficacy and preliminary toxicology profiles were assessed and compared in vivo in an adjuvant-induced arthritis (AA) rat model in order to identify the ideal prodrug design for the most effective and safe treatment of inflammatory arthritis. The in vivo data demonstrated that the C3 hydrazone linker-containing prodrug design was the most effective in preserving joint structural integrity. The results from this study suggest that the design and screening of different activation mechanisms may help to identify macromolecular prodrugs with the most potent therapeutic efficacy and safety for the management of inflammatory arthritis.

  DOI：

  10.1016/j.jconrel.2020.05.028
• 作为产物：
  描述：

  tert-butyl (3-methacrylamidopropyl)carbamate 在 盐酸 作用下， 以 甲醇 、 二氯甲烷 、 乙酸乙酯 为溶剂， 生成 N-(3-aminopropyl)methacrylamide
  参考文献：
  名称：

  一种光敏感型化合物及其制备方法和应用

  摘要：

  本发明公开了一种光敏感型化合物及其制备方法和应用，涉及蛋白质核酸共固定技术领域，光敏感型化合物是一种聚丙烯酰胺化合物，包括四唑基团和呋喃基团；由N‑(3‑氨基丙基)氨基甲酸叔丁酯、甲基丙烯酰氯呋喃‑2‑基硼酸和[羟基(苯基)‑λ3‑碘基]4‑甲基苯磺酸盐等原料制备而成；可制成蛋白质核酸共固定电泳凝胶，定量或半定量检测单细胞或多细胞中蛋白质与核酸；还可以用于微芯片电泳迁移率分析、蛋白免疫印迹、核酸印迹杂交、单细胞蛋白免疫印迹、单细胞northern/southern印迹杂交或毛细管电泳蛋白免疫印迹。本发明的蛋白质核酸共固定凝胶可同时原位固定蛋白质与核酸来研究蛋白质与DNA相互作用。

  公开号：

  CN112920174B

文献信息

• PRODUCTION OF OPHTHALMIC DEVICES BASED ON PHOTO-INDUCED STEP GROWTH POLYMERIZATION
  申请人：Medina Arturo Norberto

  公开号：US20110269869A1

  公开（公告）日：2011-11-03

  The invention provide a new lens curing method for making hydrogel contact lenses. The new lens curing method is based on actinically-induced step-growth polymerization. The invention also provides hydrogel contact lenses prepared from the method of the invention and fluid compositions for making hydrogel contact lenses based on the new lens curing method. In addition, the invention provide prepolymers capable of undergoing actinically-induced step-growth polymerization to form hydrogel contact lenses.

  这项发明提供了一种新的透镜固化方法，用于制造水凝胶隐形眼镜。这种新的透镜固化方法基于光引发的步聚合反应。该发明还提供了通过该发明方法制备的水凝胶隐形眼镜，以及基于新的透镜固化方法制造水凝胶隐形眼镜的液体组合物。此外，该发明提供了能够经历光引发的步聚合反应形成水凝胶隐形眼镜的预聚合物。
• [EN] FORCE-RESPONSIVE POLYMERSOMES AND NANOREACTORS; PROCESSES UTILIZING THE SAME<br/>[FR] POLYMERSOMES ET NANORÉACTEURS SENSIBLES À LA FORCE; PROCÉDÉS LES UTILISANT
  申请人：ADOLPHE MERKLE INSTITUTE UNIV OF FRIBOURG

  公开号：WO2019034597A1

  公开（公告）日：2019-02-21

  The mechanically induced melting properties of DNA were employed to achieve force labile membranes is described. Nucleobase pairs were used as mechanophores. Adenine and thymine functionalized complementary amphiphilic block copolymers were self-assembled into polymersomes. The nucleobases formed hydrogen bonds which were disrupted upon force stimulation. The exposure of the disconnected nucleobases to the hydrophobic matrix of the membranes lead to a change of permeability which permitted the exchange of water-soluble molecules throughout the polymer matrix. Moreover, the encapsulation of horseradish peroxidase enabled the reaction of luminol with hydrogen peroxide to yield a luminescence producing species similar to the marine bioluminescence. Moreover, the same nano-reactors were employed to catalyze the formation of a polyacrylamide gel when force was applied. Insights into the change of permeability of supramolecular networks upon force are provided. These systems are useful for drug delivery, as nanoreactors and for the selective release of curing agents for 3D printing, or fragrances.

  DNA的机械诱导熔化特性被用来实现易受力破裂的膜。核碱基对被用作机械感受器。腺嘌呤和胸腺嘧啶功能化的互补两性分块共聚物自组装成聚合体囊。核碱基形成氢键，在受力刺激下被破坏。断开的核碱基暴露在膜的疏水基质中，导致渗透性的改变，从而允许水溶性分子在聚合物基质中交换。此外，封装辣根过氧化物酶使得辣根酰胺与过氧化氢反应产生类似海洋生物发光的发光物种。此外，当施加力时，相同的纳米反应器被用来催化聚丙烯酰胺凝胶的形成。提供了关于受力下超分子网络渗透性变化的见解。这些系统可用于药物传递、纳米反应器以及用于3D打印的固化剂或香料的选择性释放。
• Process for preparing vinyl substituted beta-diketones
  申请人：Southard E. Glen

  公开号：US20060069288A1

  公开（公告）日：2006-03-30

  A process for preparing vinyl substituted beta-diketones includes reacting a halogen-containing beta-diketone with an olefin in a reaction zone under Heck coupling reaction conditions in the presence of a catalyst, a base, and an organic phosphine to provide a vinyl substituted beta-diketone product.

  制备乙烯基取代的β-二酮的方法包括在反应区域中，在存在催化剂、碱和有机膦的条件下，将含卤素的β-二酮与烯烃进行 Heck 偶联反应，从而得到乙烯基取代的β-二酮产物。
• POLYMERIC SYSTEMS FOR THE DELIVERY OF ANTICANCER DRUGS
  申请人：Lee Young B.

  公开号：US20110086111A1

  公开（公告）日：2011-04-14

  The present invention relates to compositions for the treatment of cancerous tissues in warm-blooded animals containing one or two anticancer agents attached to polymeric carriers having monomer units derived from one or more of N-(2-carboxypropyl)methacrylamide (2-CPMA), N-(3-carboxypropyl)methacrylamide (3-CPMA), N-(2-aminopropyl)methacrylamide (2-APMA) and/or N-(3-aminopropyl)methacrylamide (3-APMA) are also included. Anticancer agents in compositions can be attached to said polymeric carrier by side-chains which can be susceptible to hydrolysis by lysosomal enzymes intracellularly. Compositions can also include a targeting ligand attached to the polymeric carrier, optionally through a second linker.

  该发明涉及用于治疗温血动物体内癌组织的组合物，其中包含附着在聚合物载体上的一种或两种抗癌药物，所述聚合物载体具有源自N-(2-羧基丙基)甲基丙烯酰胺(2-CPMA)、N-(3-羧基丙基)甲基丙烯酰胺(3-CPMA)、N-(2-氨基丙基)甲基丙烯酰胺(2-APMA)和/或N-(3-氨基丙基)甲基丙烯酰胺(3-APMA)中的一个或多个单体单元。组合物中的抗癌药物可以通过在细胞内易受溶酶体酶水解的侧链附着在所述聚合物载体上。组合物还可以包括附着在聚合物载体上的靶向配体，可选地通过第二连接剂连接。
• NUCLEIC ACID PURIFICATION METHOD
  申请人：Erbacher Christoph

  公开号：US20110319506A1

  公开（公告）日：2011-12-29

  The present invention relates to a method for purifying nucleic acids using a nucleic acid-binding phase which is furnished with a deficit of nucleic acid-binding groups A having a pK of 8 to 13, or which has groups A and binding-inhibiting groups N which are neutrally charged during the binding, and preferably during the elution, and the method comprises the following steps: (a) binding the nucleic acids to the nucleic acid-binding phase at a pH which is below the pH of the pK of the nucleic acid-binding groups A (binding pH); (b) eluting the nucleic acids at a pH which is above the binding pH (elution pH). In addition, corresponding kits and also nucleic acid-binding phases which can be used for purifying nucleic acids are disclosed. The technology according to the invention permits the purification of nucleic acids and, in particular, elution, with use of low salt concentrations, and so the purified nucleic acids can be directly processed, for example used in a PCR.

  本发明涉及一种利用具有pK值为8至13的核酸结合基团A的核酸结合相或具有在结合期间和最好在洗脱期间呈中性电荷的基团A和结合抑制基团N的核酸结合相来纯化核酸的方法，该方法包括以下步骤：(a)在低于核酸结合基团A的pK值的pH下（结合pH）将核酸结合到核酸结合相上；(b)在高于结合pH的pH下（洗脱pH）洗脱核酸。此外，还公开了相应的用于纯化核酸的试剂盒和核酸结合相。根据本发明的技术允许纯化核酸，特别是在低盐浓度下进行洗脱，因此纯化的核酸可以直接处理，例如用于PCR。